Compare Global X Copper Miners ETF (COPX) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Johnson & Johnson — how do they compare? Global X Copper Miners ETF trades at $85.75 (market cap $7.10B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 87.1× Global X Copper Miners ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while Global X Copper Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 51 Days and Johnson & Johnson for 129 Days on average.
| COPX | JNJ | |
|---|---|---|
Market Cap | $7.10B | $618.09B |
Volume | 2,871,128 | 6,050,983 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $96.45 | $278.43 |
52-Week Low | $57.43 | $186.00 |
Typical Hold Time | 51 Days | 129 Days |
Enterprise Value | — | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX (Global X Copper Miners ETF) trades at $85.75, up 2.6% with a bearish technical outlook from moving averages. The ETF faces mixed sentiment as copper demand surges due to AI and electrification trends, while miner stocks lag behind metal prices. Recent articles highlight copper's strategic importance but note global surplus concerns and Federal Reserve policy impacts on mining equities.
Outlook hinges on copper price sustainability amid AI-driven demand, though miner valuations remain pressured. Key risks include global copper surplus projections and Fed policy volatility. Opportunities exist from structural copper deficits and operational leverage if metal prices hold near record highs above $6.85/lb (GuruFocus, September 8, 2026).
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
